Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

✍ Scribed by Nicolaus Kröger; Jose A. Perez-Simon; Han Myint; Hans Klingemann; Avichai Shimoni; Arnon Nagler; Rodrigo Martino; Adrian Alegre; Jose F. Tomas; Rainer Schwerdtfeger; Michael Kiehl; Axel Fauser; Herbert Gottfried Sayer; Angel Leon; Jörg Beyer; Tatjana Zabelina; Francis Ayuk; Jesus F. San Miguel; Ronald Brand; Axel Rolf Zander

• Book ID: 116277874
• Publisher: Elsevier Science
• Year: 2004
• Tongue: English
• Weight: 289 KB
• Volume: 10
• Category: Article
• ISSN: 1083-8791
• DOI: 10.1016/j.bbmt.2004.06.002